Right Ventricular Dysfunction in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is one of the primary diseases affecting the cardiac muscle and is characterized by heterogeneous genetic, morphological, functional and clinical features. It is the most common genetic heart disease, with an estimated prevalence at 0.2%. Structural abnormalities in the RV are present in a great proportion of patient with HCM. With advancements of echocardiography, and improved diagnosis the percentage of RV hypertrophy (RVH) in HCM is augmented to 53%. The main common finding in this situation is the mild ventricular obstruction.
There are no specific symptoms related to the RV dysfunction in HCM. There is no demonstrated correlation between the sites and the severity of the LV obstruction and the clinical symptoms. Therefore, the development of the heart failure signs and symptoms, ventricular and/or supraventricular arrhythmias or sudden deaths are most often impossible to predict. There is no specific medical treatment for RV dysfunction in HCM. In absence of the significant gradient in the LV outflow, the patients are treated with “normal” therapy of HCM, consisting in beta-blockers and calcium-channel blockers. In case of significant RV gradient, surgical intervention has been reported. The standard surgical approach consist in myectomy (Morrow procedure) and relief of the RV gradient by resection and patch enlargement. The results are very good, symptoms are improved at intermediate-term follow-up and sudden deaths are rare.
KeywordsRight ventricle Hypertrophic cardiomyopathy Right ventricle dysfunction
- 1.Wynne J, Braunwald E. The cardiomyopathies and myocarditides. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: WB Saunders Company; 1997. p. 1414.Google Scholar
- 2.Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699–708.CrossRefPubMedGoogle Scholar
- 13.D’Andrea A, Caso P, Bossone E, Scarafile R, Riegler L, Di Salvo G, et al. Right ventricular myocardial involvement in either physiological or pathological left ventricular hypertrophy: an ultrasound speckle-tracking two-dimensional strain analysis. Eur J Echocardiogr. 2010;11:492–500.CrossRefPubMedGoogle Scholar